mProX™ Human CD80 Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Mesenchymal stem cells

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Infectious Research

Related Diseases

Vaccinia; Lymphocytic Choriomeningitis

Gene ID

Human:941

UniProt ID

Human:P33681

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD80 is a marker used to study the phenotypic characteristics and plasticity of alveolar macrophages in rats with metabolic syndrome. It has been found that metabolic syndrome decreases the number of alveolar macrophages with the M1 phenotype, but does not affect their phenotypic plasticity in culture. However, under the action of M2 reprogramming factors, these cells demonstrate a wide range of phenotypic plasticity by the CD80 marker. CD80 is also involved in the production of cathepsins B and S by macrophages and their polarizations. A rhenium(I)-diselenoether drug has been shown to decrease the expression of cathepsins B and S in M1 macrophages and increase the expression of M1 markers while decreasing the expression of M2 markers. In cystic vestibular schwannoma, CD80 expression in cyst fluid correlates with the expression of monocyte chemotactic protein-1 (MCP-1) in tumor tissue, suggesting a role in monocyte recruitment and macrophage polarization. Additionally, CD80 is used as a biomarker in the evaluation of the efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Cosibelimab demonstrated a clinically meaningful objective response rate and duration of response with a manageable safety profile. Finally, CD80 is involved in tumor-specific immunity for colon tumor treatment. Reactive oxygen species-sensitive biodegradable mesoporous silica nanoparticles loaded with a therapeutic vaccine (TheraVac) containing CD80 induce the maturation and activation of dendritic cells, leading to robust antitumor immune responses and complete cure of colon tumors in mice.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human CD80 Stable Cell Line (S01YF-1023-PY178). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Alex Smith (Verified Customer)

How does CD80 interact with CTLA-4 and PD-1 in immune regulation? Dec 13 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

CD80 plays a role in immune regulation by interacting with CTLA-4 and PD-1. CTLA-4 can regulate PD-L1:PD-1 interaction via transendocytosis of CD80, modulating immune responses. Dec 13 2022

chat Taylor Jones (Verified Customer)

Can CD80 be used in cancer immunotherapy? Aug 04 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

CD80-Fc fusion proteins have potential in cancer immunotherapy, enhancing tumor-specific immunity by overcoming PD-L1-induced immune suppression. Aug 04 2022

Published Data

Fig.1 Silencing the CD80 gene through siRNA led to a reduction in the inhibitory capabilities of CD80-positive, Gr-1-positive, CD11b-positive mesenchymal stem cells associated with ovarian carcinoma.

Inhibiting CD80 expression through siRNA significantly reversed the suppressive effects exerted by Gr-1CD11b+ cells associated with ovarian carcinoma on the production of IFN-γ in VLP-specific splenocyte cultures (VLP.SC). These CD80-depleted Gr-1+ cells, isolated from the ascites of mice afflicted with MOSEC 1D8 ovarian carcinoma, exhibited a distinct reversal in their regulatory capabilities compared to CD80-expressing Gr-1+ cells transfected with CD80 siRNA, and control siRNA-transfected Gr-1+ cells.

Ref: Yang, Rongcun, et al. "CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+ CD11b+ myeloid cells." Cancer research 66.13 (2006): 6807-6815.

Pubmed: 16818658

DOI: 10.1158/0008-5472.CAN-05-3755

Research Highlights

Collery, Philippe. et al. "Remarkable Effects of a Rhenium(I)-diselenoether Drug on the Production of Cathepsins B and S by Macrophages and Their Polarizations." Current pharmaceutical design, 2023.
In this study, the researchers aimed to investigate the effects of anticancer rhenium(I)-diselenoether (Re-diSe) on the production of cathepsins B and S by tumor-associated macrophages (TAMs). Specifically, they examined the impact of Re-diSe on M1 macrophages induced by lipopolysaccharides (LPS) and M2 macrophages induced by interleukin 6 (IL-6). The results of this study shed light on the potential of Re-diSe in regulating the excessive production of cysteine proteases by TAMs, making it a promising therapeutic approach for cancer treatment.
Collery, Philippe. et al. "Remarkable Effects of a Rhenium(I)-diselenoether Drug on the Production of Cathepsins B and S by Macrophages and Their Polarizations." Current pharmaceutical design, 2023.
Pubmed: 37859327 DOI: 10.2174/0113816128268963231013074433

Nisenbaum, Eric. et al. "Cytokine Profiling of Cyst Fluid and Tumor-Associated Macrophages in Cystic Vestibular Schwannoma." Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2023.
The vestibular schwannoma (VS) secretome is known to trigger the recruitment of monocytes and the polarization of macrophages into either M1 (proinflammatory) or M2 (protumorigenic) phenotypes. These macrophages, in turn, secrete cytokines that play a role in shaping the tumor microenvironment. Profiling the cyst fluid and cerebrospinal fluid (CSF) of cystic VS offers a distinct chance to gain insights into the mechanisms underlying tumor progression and cyst development.
Nisenbaum, Eric. et al. "Cytokine Profiling of Cyst Fluid and Tumor-Associated Macrophages in Cystic Vestibular Schwannoma." Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2023.
Pubmed: 37853737 DOI: 10.1097/MAO.0000000000004032